Revvity (PKI) Stock Price, News & Analysis

Company Overview

Revvity, Inc provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics.? The company was founded by Richard Scott Perkin and Charles W. Elmer on April 19, 1937, and is headquartered in Waltham, MA.

Key Stats

• Today's Range: N/A
• 50-Day Range: $115.24 to $137.11
• 52-Week Range: N/A
• Volume: 1.63 million shs
• Average Volume: 851,117 shs
• Market Capitalization: $14.57 billion
• P/E Ratio: 15.01
• Dividend Yield: 0.24%
• Price Target: $54.00
• Consensus Rating: Buy

Revvity Stock Analysis - MarketRank™

Revvity scored higher than 88% of companies evaluated by MarketBeat, and ranked 148th out of 1,003 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Revvity has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Revvity has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 4.4 / 5
• Proj. Earnings Growth: 17.71%

Earnings Growth

Earnings for Revvity are expected to grow by 17.71% in the coming year, from $4.97 to $5.85 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.74.

Price to Earnings Ratio vs. Sector

The P/E ratio of Revvity is 15.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 145.31.

Price to Earnings Growth Ratio

Revvity has a PEG Ratio of 0.50. PEG Ratios below 1 indicate that a company could be undervalued.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for PKI.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Revvity has a dividend yield of 0.24%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Revvity does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Revvity is 3.65%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Revvity will have a dividend payout ratio of 4.79% next year. This indicates that Revvity will be able to sustain or increase its dividend.

Sustainability and ESG

• Score: 3.5 / 5
• Environmental Score: -1.99

Short Interest

There is no current short interest data available for PKI.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 2 people have searched for PKI on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Revvity insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.52% of the stock of Revvity is held by insiders.

Percentage Held by Institutions

85.22% of the stock of Revvity is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PKI Stock Analysis - Frequently Asked Questions

How were Revvity's earnings last quarter?

Revvity, Inc. (NYSE:PKI) announced its quarterly earnings results on Thursday, May, 11th. The medical research company reported $1.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.07 by $0.06. The medical research company had revenue of $674.87 million for the quarter, compared to analyst estimates of $686.30 million. Revvity had a net margin of 28.94% and a trailing twelve-month return on equity of 11.17%.

Is Revvity doing a stock buyback?

Revvity's Board of Directors approved a stock repurchase program on Thursday, May 11th 2023, which authorizes the company to repurchase $600,000,000 in outstanding shares, according to EventVestor. This means that the company could repurchase up to 4.1% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's leadership believes its stock is undervalued.

Does Revvity have any subsidiaries?

Revvity subsidiaries include these companies: BioLegend, Immunodiagnostic Systems, Nexcelom Bioscience, SIRION Biotech, Oxford Immunotec, Horizon Discovery, Cisbio.com, and more.

What other stocks do shareholders of Revvity own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Revvity investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), NVIDIA (NVDA), Johnson & Johnson (JNJ), Pfizer (PFE), Home Depot (HD) and Bristol-Myers Squibb (BMY).

Company Calendar

• Last Earnings: 5/11/2023
• Today: 9/24/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Analytical instruments
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:PKI
• CUSIP: 71404610
• CIK: 31791
• Web: www.perkinelmer.com
• Phone: (781) 663-6900
• Fax: 781-663-5985
• Employees: 16,700
• Year Founded: 1937

Price Target and Rating

• Average Stock Price Target: $54.00
• High Stock Price Target: $54.00
• Low Stock Price Target: $54.00
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): $7.68
• Trailing P/E Ratio: 15.01
• Forward P/E Ratio: N/A
• P/E Growth: 0.5
• Net Income: $569.18 million
• Net Margins: 28.94%
• Pretax Margin: 13.81%
• Return on Equity: 11.17%
• Return on Assets: 5.83%

Debt

• Debt-to-Equity Ratio: 0.48
• Current Ratio: 2.43
• Quick Ratio: 2.15

Sales & Book Value

• Annual Sales: $3.31 billion
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 9.88
• Book Value: $58.49 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 126,410,000
• Free Float: 125,755,000
• Market Cap: $14.57 billion
• Optionable: Optionable
• Beta: 1.10